The controversy around anti-amyloid antibodies for treating Alzheimer’s disease
Philip Hunter
Abstract
The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease.
Topics & Concepts
Amyloid (mycology)AntibodyDiseaseAlzheimer's diseaseMedicineAmyloid βImmunologyVirologyPathologyAlzheimer's disease research and treatmentsComputational Drug Discovery MethodsTryptophan and brain disorders